However, it is essential to acknowledge that neither cetuximab (an EGFR inhibitor) nor bevacizumab (a VEGFR inhibitor) has exhibited superior efficacy in the context of first-line treatment among patients with KRAS-mutated metastatic colorectal carcinoma (mCRC) [29], while combinations such as EGFR inhibitors with PARP, which is a family of proteins involved in a number of cellular process, such as DNA repair and genomic stability, inhibitors (olaparib) have effectively curbed tumor growth in KRAS-mutant cancer cell-derived xenograft models [30]. The gene discussed is EGFR; the disease is neoplasm.